News

Press Releases

Proclara Biosciences to Participate in Mizuho Biotechnology Conference 2017: CNS “Deep Management” Day
September 12, 2017

 

Proclara Biosciences Presents New Preclinical Data Supporting the Development of NPT189 at Alzheimer’s Association International Conference (AAIC) 2017
July 18, 2017

 

Proclara Biosciences Announces Pipeline Progress
July 17, 2017

 

Proclara Biosciences Appoints Suzanne Bruhn, Ph.D., as Chief Executive Officer to Guide Development of Novel Approach for Neurodegenerative Disease s  
April 26, 2017

 

Proclara Biosciences Australia, a subsidiary of Proclara Biosciences, awarded grant by Biopharmaceuticals Australia to help develop new biotherapy with blockbuster potential
March 10, 2017

 

Proclara Biosciences to Present at Cowen and Company 37th Annual Health Care Conference
March 1, 2017

 

Proclara Biosciences to Present at 28th Annual Piper Jaffray Healthcare Conference
November 23, 2016


Proclara Biosciences Awarded Part the Cloud Grant from Alzheimer’s Association to Support Development of NPT088 for Alzheimer’s Disease
November 18, 2016


Proclara Biosciences Announces Newly Issued U.S. Patents for its Core Technology Targeting Protein Misfolding Disorders
November 16, 2016


Proclara Biosciences Announces $47 Million in New Investment to Support the Development of Product Candidates in Alzheimer’s, Parkinson’s and Other Diseases
September 07, 2016


Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease
September 07, 2016
 

Note: prior to September, 2016, Proclara Biosciences was known as NeuroPhage Pharmaceuticals.

 

NeuroPhage’s NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer’s Association International Conference
July 19, 2015


NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer’s Association International Conference
July 13, 2015


NeuroPhage to Participate on Neuroscience Drug Development Panel at MassBio Annual Meeting March 27, 2015
March 20, 2015


NeuroPhage to Present at 12th International Conference on Alzheimer’s & Parkinson’s Diseases
March 16, 2015


NeuroPhage Expands Series D Financing to $27 Million
January 14, 2015

In the News

Targeting toxic proteins: Novel drug approaches to defeat dementias
Patricia F. Fitzpatrick Dimond, GEN
December 2, 2016

 

New clues to target Alzheimer’s found in proteins
Shirley S. Wang, Wall Street Journal
July 20, 2015

 

Alzheimer’s drugs in the works might treat other diseases, too
Jon Hamilton, NPR
July 22, 2015

 

Universal plaque-busting drug could treat various brain diseases
Andy Coghlan, New Scientist
July 11, 2015

 

The bright side of Parkinson’s
Jon Palfreman, New York Times
February 21, 2015


Media Contact
Sarah Sutton
Ten Bridge Communications
518-932-3680
sarah@tenbridgecommunications.com

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
(212) 362-1200
hannahd@sternir.com